Stay updated with breaking news from Actimed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
Provides extended UK patent coverage relating to lead compound S-pindolol benzoate (ACM-001.1) to 2040. International patent application also filed in March 2021. LONDON, May 4, 2022 /PRNewswire/
- Actimed Therapeutics initiates the company's first clinical study of the pharmacokinetics and pharmacodynamics (PK/PD) for a new salt of S-pindolol (ACM-001.1) - This study is a prelude